Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Bioadaptives (BDPT) Total Liabilities (2016 - 2025)

Bioadaptives' Total Liabilities history spans 8 years, with the latest figure at $2.4 million for Q4 2025.

  • On a quarterly basis, Total Liabilities rose 36.51% to $2.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $2.4 million, a 36.51% increase, with the full-year FY2025 number at $2.4 million, up 36.51% from a year prior.
  • Total Liabilities hit $2.4 million in Q4 2025 for Bioadaptives, up from $1.6 million in the prior quarter.
  • Over the last five years, Total Liabilities for BDPT hit a ceiling of $2.4 million in Q4 2025 and a floor of $1.2 million in Q1 2021.
  • Historically, Total Liabilities has averaged $1.6 million across 5 years, with a median of $1.6 million in 2022.
  • The widest YoY moves for Total Liabilities: up 36.51% in 2025, down 27.07% in 2025.
  • Tracing BDPT's Total Liabilities over 5 years: stood at $1.2 million in 2021, then increased by 19.91% to $1.5 million in 2022, then rose by 17.59% to $1.8 million in 2023, then decreased by 1.42% to $1.7 million in 2024, then skyrocketed by 36.51% to $2.4 million in 2025.
  • Business Quant data shows Total Liabilities for BDPT at $2.4 million in Q4 2025, $1.6 million in Q3 2025, and $1.4 million in Q2 2025.